What are the functions of venetoclax?

Venetoclax is a targeted therapy drug mainly used to treat certain hematological malignancies. Its key role is to induce apoptosis of cancer cells by selectively inhibiting BCL-2 (BCL-2) protein, thereby inhibiting the growth and spread of tumors. BCL-2Protein is an anti-apoptotic protein that is highly expressed in a variety of cancer cells, helping cancer cells to evade immune system attacks and prevent cell death. By blocking the action of this protein, venetoclax causes cancer cells to lose their survival mechanisms and naturally undergo apoptosis.

The effects of venetoclax are mainly reflected in the treatment of the following types of diseases:

1. Chronic lymphocytic leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a common hematological malignancy, especially among the elderly. CLLLeukemia cells in patients are often accompanied by overexpression of BCL-2 protein, which allows these cells to avoid apoptosis and continue to grow and proliferate. Venetoclax promotes the death of leukemia cells by inhibiting the BCL-2 protein, significantly reducing the number of cancer cells and thus controlling the progression of the disease.

Venetoclax is often used in patients with CLL that is resistant to or has relapsed from other treatments, especially those with high-risk 17p chromosomal deletions or TP53 gene mutations. These patients respond poorly to standard chemotherapy and immunotherapy, so venetoclax provides a new treatment option for these patients.

2. Small lymphocytic lymphoma (SLL)

Small lymphocytic lymphoma (SLL) is another type of non-Hodgkin lymphoma that is closely related to CLL and the two are very similar in biological characteristics. SLL is also a chronic disease in which cancer cells spread in the bone marrow, lymph nodes and spleen and have high BCL-2 protein expression. Through the same mechanism, venetoclax can effectively kill the malignant cells of SLL and help control the disease.

When treatingSLL, venetoclax can be used in combination with other drugs, such as rituximab (Rituximab), to enhance its efficacy. Multiple clinical studies have shown that this combination therapy can extend progression-free survival and significantly reduce the chance of disease recurrence.

3. Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) is a rapidly progressive form of leukemia that usually affects older patients or those who are too frail to tolerate intense chemotherapy. For these patients, the side effects of traditional chemotherapy may be too severe, necessitating a gentler yet effective treatment regimen.

Venetoclax is usually used in combination with drugs such as azacitidine (Azacitidine) or decitabine (Decitabine) in the treatment of AML. By inhibiting BCL-2, venetoclax can effectively kill AML malignant cells and synergize with other drugs to further enhance the efficacy. Studies have shown that for AML patients who cannot tolerate high-intensity chemotherapy, venetoclax treatment can significantly improve the remission rate and prolong the patient's survival.

4. Other potential indications

In addition to CLL, SLL and AML, venetoclax has attracted widespread attention for potential applications in other B cell malignancies. Research is exploring its role in multiple myeloma, Hodgkin lymphoma and other blood disorders. Since BCL-2 is highly expressed in a variety of cancers, the targeting mechanism of venetoclax makes it possible to show effectiveness in the treatment of more types of cancer.

Role in combination therapy:In actual clinical applications, venetoclax is often used in combination with other anti-cancer drugs to enhance its efficacy. For example, in the treatment of CLL, venetoclax combined with rituximab, ibrutinib (Ibrutinib) and other drugs can prolong progression-free survival and reduce the risk of recurrence. In the treatment of AML, venetoclax is combined with low-dose chemotherapy drugs to better control the disease. These combination therapies are designed to not only improve efficacy but also reduce patient resistance to a single drug.

Advantages of venetoclax: Venetoclax has the advantages of strong targeting and relatively mild side effects. Compared with traditional chemotherapy drugs, venetoclax can selectively act on cancer cells without causing too much damage to healthy cells. Therefore, when patients use this drug, they often do not need to endure the serious side effects of chemotherapy, such as hair loss, nausea, and vomiting.

For those patients who are ineffective or relapse under traditional therapies, venetoclax provides a more targeted and effective treatment, especially in high-risk patients or elderly patients, and the drug's tolerability and efficacy have been clinically proven.